Novartis Provides Update On Phase Iii Stand Trial Assessing Crizanlizumab

Novartis Announced That The Preliminary Results From The Ongoing Global Phase Iii Study Stand (Nct03814746) Indicate No Statistically Significant Difference Between Crizanlizumab 5Mg/Kg Or Crizanlizumab 7.5Mg/Kg And Placebo In Annualized Rates Of Vaso-Occlusive Crises (Pain Crises) Leading To A Healthcare Visit Over The First-Year Post Randomization. These Findings Are Inconsistent With Previous Trial Results From Sustain (Nct01895361), Which Demonstrated The Superiority Of Crizanlizumab 5.0Mg/ Kg Compared To Placebo. It Is Important To Note That The Preliminary Results Do Not Suggest New Safety Concerns With Crizanlizumab. The Overall Safety Profile Of Crizanlizumab Remains Consistent With The Known Profile Of The Commercially Available 5.0Mg/Kg Dose. Since Informing Regulatory Authorities, The European Medicines Agency

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!